Weigao Blood Purification: Announcement on self-examination of insider trading in the issuance of shares to purchase assets by informed persons.

Weigao Blood Purification announced that the company plans to issue shares to purchase 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. The self-examination period is from May 19, 2025 to January 5, 2026, and the verification scope includes the listed company, the trading counterparty, and other relevant subjects and personnel. During the self-examination, it was found that Xu Chengling, a staff member of the securities affairs department of the listed company and a direct relative, bought and sold 1400 shares, and the controlling shareholder, director Zhao Chunxu, bought and sold 7500 shares. Both claimed to have not traded using insider information, and they no longer hold shares at the end of the self-examination period. They have also promised not to trade again until the restructuring is completed. After the company's self-examination and verification by intermediaries, the buying and selling activities of the relevant parties do not constitute insider trading and do not affect this restructuring.